Redbiotec is a private biotech company in Zurich-Schlieren. Founded in 2006 as a spin-off of ETH Zürich, the company has won several awards, including the renowned W.A. de Vigier Award.
In 2015, Pfizer acquired Redvax (a Redbiotec spin-off) for its CMV vaccine program and technology platform. Redbiotec has also closed deals with other global industry partners.
Redbiotec is backed by experienced institutional and private investors. Key investors include Zürcher Kantonalbank – Switzerland’s largest cantonal bank with S&P AAA credit rating since 1994, and Redalpine Capital, a European seed and early-stage venture investor.